[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-cardiovascular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-cardiovascular":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,77,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100586153","emg-control-assistance-virtual-reality-interface-coupled-with-cerebellar-itbs-for-arm-recovery-after-stroke-erica-100586153",false,"NCT06911671","EMG Control Assistance Virtual Reality Interface Coupled With Cerebellar-iTBS for Arm Recovery After Stroke (ERICA)","Innovative Upper Limb Stroke Rehabilitation Approach Combining Myoelectric Control Assistance in Virtual Reality and Cerebellar TBS Plasticity Enhancement","ERICA","Inclusion Criteria:\n\n* First ever ischemic stroke with mild to moderate motor impairment of upper limb;\n* Left or right sub-cortical or cortical lesion of the middle cerebral artery;\n* Age\\>18, \\\u003C80 years;\n* No visuospatial, cognitive, or attention deficits;\n* Fugl-Meyer score\\\u003C56.\n\nExclusion Criteria:\n\n* History of seizures;\n* Treatment with Benzodiazepines, Baclofen;\n* Pregnancy status;\n* Intracranial metal implant;\n* Cardiac pace-maker;\n* Orthopedic upper limb limitation;\n* Upper limb pain;\n* Patients with neurological diseases beyond stroke or with neuropsychiatric disorders or with neuropsychological disorders that could potentially compromise informed consent or compliance during the study.","ALL","18 Years","80 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"NA","The investigators hypothesize that a myoelectric (EMG) controlled virtual reality (VR) interface allows for effective upper limb motor recovery of stroke patients. EMG control offers the possibility to alter visual feedback according to the recorded muscle activity in real-time. By manipulating the motion of a virtual hand associated with the recorded muscle patterns, assistance can be provided to stroke patients by correcting the error between the actual (dysfunctional) and a reference (functional) muscle pattern. Thus, through such an assistive EMG control algorithm, patients will be able to perform reaching movements with the virtual hand despite their motor impairment. By gradually reducing assistance, it is hypothesized that the salient error in the task space provided as visual feedback will systematically change the muscle patterns, thereby driving adaptation of the dysfunctional muscle patterns, enhancing motor recovery. Moreover, due to its relevant role in motor learning, it is expected that cerebellar stimulation will favor the underlying processes of adapting cerebello-cortical plasticity involved in motor learning. Therefore, it is hypothesized that an assistive EMG control algorithm in combination with cerebellar transcranial magnetic stimulation will further enhance upper limb recovery.",[28,29],"Stroke","Stroke, Cardiovascular",[31,32,33,34,35,36,37],"Virtual Reality","Brain Stimulation","Myoelectric Control","Transcranial Magnetic Stimulation","Cerebellar Stimulation","Motor Recovery","Tailored Assistance","RECRUITING","2026-01-30",{"date":41,"type":42},"2026-02-03","ACTUAL",{"date":44,"type":42},"2025-04-01",{"date":46,"type":22},"2027-10-01",{"name":48,"class":49},"I.R.C.C.S. Fondazione Santa Lucia","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100559821","efficacy-of-a-telehealth-delivered-group-lifestyle-balance-for-people-post-stroke-tglb-cva-100559821","NCT06569121","Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)","Efficacy of an Evidence-based Telehealth-delivered Weight-loss Intervention to Enhance Access and Reach Underserved Groups After Stroke","tGLB-CVA","Inclusion Criteria:\n\n* Body Mass Index ≥25\n* All types of stroke\n* Able to Participate in Physical Activity\n* ≥12 months post first stroke\n* Have internet, phone, or computer access, or be willing to use one provided by the study team\n\nExclusion Criteria:\n\n* Contraindications for physical activity\n* Low Cognitive Function\n* Residing in hospital, acute rehab, skilled nursing facility\n* Not fluent in the English language\n* Pre-existing eating disorder\n* Pregnancy","85 Years",{"count":61,"type":22},94,[25],"Investigators will conduct a randomized controlled trial (RCT) to assess intervention efficacy of telehealth delivery of the GLB-CVA (tGLB-CVA) compared to a 6-month wait-list control (WLC) in partnership with a diverse group of patient partners and peer mentors.",[65,28,29,66,67],"Stroke, Acute","Stroke (CVA) or TIA","Stroke\u002FBrain Attack","2026-01-19",{"date":70,"type":42},"2026-01-21",{"date":72,"type":42},"2024-12-07",{"date":74,"type":22},"2029-12-31",{"name":76,"class":49},"Baylor Research Institute",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":50},"100553218","implementation-of-ivs3-for-upper-limb-motor-recovery-100553218","NCT06483230","Implementation of IVS3 for Upper Limb Motor Recovery","A Pilot Study on Tolerance and Ease of Implementation of Intensive Visual Stimulation (IVS3) in Daily Practice for Upper Limb Motor Recovery in Outpatient Rehab Center","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. English speaking\n3. History of ischemic or hemorrhagic stroke ≥ 6 months prior to study enrolment\n4. FMA-UE: 20 \\\u003C x \\\u003C 50 (moderate impairments)\n5. With or without hemi spatial neglect\n\nExclusion Criteria:\n\n1. Spasticity or increased tone with MAS ≥3 in the upper extremity\n2. Unable to communicate effectively or provide informed consent\n3. Significant visual impairments\n4. Concurrent occupational therapy being received outside of the study\n5. Pregnant or incarcerated individuals",{"count":85,"type":22},25,[25],"This study measures participant satisfaction and upper extremity function in outpatients with chronic stroke when exposed to the IVS3 device. Investigators hypothesize that treatment with the IVS3 device will be feasible and tolerable for use in the outpatient setting.",[89,29,90,91],"Neglect, Hemispatial","Mirror Movement","Motor Activity","2025-10-27",{"date":94,"type":42},"2025-10-29",{"date":96,"type":42},"2024-10-02",{"date":98,"type":22},"2027-06",{"name":100,"class":49},"Weill Medical College of Cornell University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":114,"conditions":115,"keywords":121,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100442801","phase-2-mlc1501-study-assessing-efficacy-in-stroke-recovery-100442801","NCT05046106","MLC1501 Study Assessing Efficacy in STROke Recovery","A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Efficacy and Safety Study of MLC1501 in Patients With Stroke","MAEStro","Inclusion Criteria:\n\n* Male or female.\n* 18 years old or older.\n* Diagnosed with acute ischemic stroke with compatible brain imaging findings between 2 days to 7 days prior to inclusion. Patients who undergo intravenous or endovascular thrombolysis or thrombectomy must be considered stable for at least 24 hours post-procedure prior to inclusion.\n* NIHSS total score of 8 to 18 (inclusive) at the time of inclusion with a combined score of at least 2 on the NIHSS motor items 5A or 5B and\u002For 6A or 6B.\n* A candidate for active rehabilitation in the opinion of the treating physician.\n* Able to comply with the requirements of the protocol and provide written informed consent by patient or legal representative before any study-specific procedure is performed.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin score of \\>1.\n* Contraindication to any of the study procedures.\n* Participation in another investigational drug or device trial within the past 30 days.\n* Intake of warfarin in the past one week or expected to be on warfarin while in the study.\n* Women who are pregnant, breastfeeding, of child-bearing potential or planning to become pregnant during the study. Menopausal\u002Fpost-menopausal women without menstruation for 12 consecutive months or surgically sterilized women may be included. Intake of oral contraceptive pills or hormone replacement therapy is not allowed. Use of mechanical barriers, e.g., condom, intrauterine device, are allowed. Local contraception requirements for clinical trials should be followed.\n* Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis, or members of the Fabaceae\u002FLeguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae\u002FUmbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip), or Quillaja bark (soapbark).\n* Evidence of other significant non-ischemic brain lesion which could affect long-term function or disability.\n* Evidence of advanced medical condition that would affect study assessment and follow-up, such as cancer, renal failure, liver cirrhosis, severe dementia, or psychosis.\n* Any other medical or psychiatric or cognitive condition which, in the study investigator's opinion, may jeopardize the patient by his\u002Fher participation in this study, may hamper his\u002Fher ability to complete procedures required in the study, affect study assessment and follow-up, or affect the validity of the study results",{"count":110,"type":22},540,[112,113],"PHASE2","PHASE3","This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.",[28,116,117,118,29,119,120],"Stroke, Ischemic","Strokes Thrombotic","Stroke Sequelae","Stroke, Embolic","Stroke, Cryptogenic",[122,123,107,124,125],"stroke","MLC1501","stroke recovery","neurorestoration","NOT_YET_RECRUITING","2023-03-14",{"date":129,"type":42},"2023-03-16",{"date":131,"type":22},"2025-01",{"date":133,"type":22},"2028-12",{"name":135,"class":136},"Moleac Pte Ltd.","INDUSTRY"]